Year-End Report 2008 January - December • Group revenues from sales of goods and royalties amounted to 1,272 (1,318) MSEK. • Earnings per share amounted to 0.34 (3.17*) SEK. • Operating income amounted to 50 (371*) MSEK. • Revenues within the Esthetics product area amounted to 1,037 (1,073) MSEK and operating income was 172 (533*) MSEK. • Income after tax amounted to 33 (315*) MSEK. October - December • Group revenues from sales of goods and royalties amounted to 336 (336) MSEK during the fourth quarter and operating income amounted to -50 (-10) MSEK. • Income after tax amounted to -44 (-14) MSEK during the fourth quarter. The results for the fourth quarter include a restructuring cost of 31 MSEK and external costs of 35 MSEK in connection with Ivytan AB's bid for Q-Med. Important events after the end of the year • Q-Med has obtained registration approval for Restylane® in China. • Q-Med and Palomar Medical Technologies, Inc., have terminated the international distribution agreement that was entered into in January 2008. • At Q-Med's Extraordinary General Meeting on February 4 a resolution was adopted to re-elect Bertil Hult, Anders Milton and Bengt Ågerup as Board members of Q-Med. Ulf Mattsson, Tomas Nicolin and Kristina Persson were newly elected. The meeting also elected Anders Milton as Chairman of the Board. • The Board proposes that no dividend be paid for 2008. * Operating income for 2007 includes the supplementary purchase sum of 200 MSEK that Q-Med received from Medicis when Restylane Perlane™ was approved for sales in the USA. Queries should be addressed to: Bengt Ågerup, President and CEO Tel: + 46 (0)70 -974 9025 Alexander Kotsinas, Vice President and CFO Tel: +46 (0)73-500 1111 Madelene Sandgren, Director Investor Relations and Corporate Communications Tel: +46 (0)70-974 9015 Q-Med AB is a biotechnology/medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, NASHA™, for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: Restylane® for filling lines and folds, contouring and creating volume in the face, Macrolane™ for body contouring, Durolane™ for the treatment of osteoarthritis of the hip and knee joints, Deflux® for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and Solesta™ for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q Med today has just over 650 coworkers, with close to 400 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic.
Year-End Report 2008
| Source: Q-Med AB
Attachments
